Exploring the Value of BRD9 as a Biomarker, Therapeutic Target and Co-Target in Prostate Cancer

Background and aims: Despite recent advances in advanced prostate cancer treatments, clinical biomarkers or treatments for men with such cancers are imperfect. Targeted therapies have shown promise, but there remain fewer actionable targets in prostate cancer than in other cancers. This work aims to...

Descripción completa

Detalles Bibliográficos
Autores principales: Barma, Nafisa, Stone, Timothy C., Carmona Echeverria, Lina Maria, Heavey, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698755/
https://www.ncbi.nlm.nih.gov/pubmed/34944438
http://dx.doi.org/10.3390/biom11121794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698755/
https://www.ncbi.nlm.nih.gov/pubmed/34944438
http://dx.doi.org/10.3390/biom11121794

Ejemplares similares